Tag: AML


FDA grants Orphan Drug Designation to Faron’s bexmarilimab in AML

August 29, 2023

Via: Pharma Times

The ODD will offer clinical development and commercialisation benefits that will strengthen the drug programme Faron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its bexmarilimab for acute myeloid leukaemia […]

Clinical Trials, Research and Development

FDA Halts Clinical Trial Enrollment for Gilead’s Magrolimab in AML Studies

August 21, 2023

Via: Biopharm International

On Aug. 21, 2023, Gilead Sciences announced that FDA has placed a partial clinical hold on the company initiating new patients into US studies for magrolimab, an investigational anti-CD47 immunotherapy, to treat acute myeloid leukemia (AML). FDA’s decision follows a […]

Clinical Trials, News, Research and Development

Moleculin Approved to Accelerate European Clinical Trial

April 28, 2020

Via: BioSpace

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it is now authorized by the Polish Department of Registration of Medicinal Products known as URPL […]

Cell and Gene Therapy, Industry, News

Gilead to Acquire Forty Seven for $4.9B, Expanding Immuno-Oncology Pipeline

March 2, 2020

Via: Genetic Engineering and Biotechnology News

Gilead Sciences has agreed to acquire Forty Seven for $4.9 billion cash, the companies said today, in a deal intended to boost the buyer’s immuno-oncology R&D pipeline—anchored by Forty Seven’s lead candidate magrolimab, which generated positive Phase Ib results nearly […]